FUNDUS AUTOFLUORESCENCE NOT PREDICTIVE OF TREATMENT RESPONSE TO INTRAVITREAL BEVACIZUMAB IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
FUNDUS AUTOFLUORESCENCE NOT PREDICTIVE OF TREATMENT RESPONSE TO INTRAVITREAL BEVACIZUMAB IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION
复制标题
DOI：
10.1097/iae.0b013e3182475aea
复制
发表时间：
2012-09-01
影响因子：
3.3
通讯作者：
Freeman, William R.
中科院分区：
文献类型：
--
作者：
Chhablani, Jay;Kozak, Igor R.;Freeman, William R.
目的：中心凹自发荧光（AF）被认为是继发于年龄相关性黄斑变性的脉络膜新生血管（CNV）治疗结果的潜在预测因子，并且可能是帮助预测患者和临床试验的有用标记。这项回顾性研究旨在确定治疗前的中心凹 AF 是否可以预测继发于年龄相关性黄斑变性的 CNV 的玻璃体腔内贝伐单抗单一疗法的治疗反应。 方法：本研究纳入了 95 只患有继发于年龄相关性黄斑变性的幼稚 CNV 的眼睛（85 名患者），接受玻璃体内贝伐单抗单一疗法治疗。病变大小、荧光素血管造影的 CNV 类型、治疗前最佳矫正视力和黄斑中心凹 AF 模式（完整/非完整）用作预测因子。分别使用最佳矫正视力变化和 6 个月时的解剖反应作为因变量进行多变量线性回归和逻辑回归。 结果：治疗前中心凹 AF（完整或非完整）不能预测视力结果（P = 0.17），病变大小（P = 0.2）或 CNV 类型（P = 0.61）也不能预测视力结果。中心凹 AF 确实与视力相关，但它不能预测任何治疗反应。治疗前最佳矫正视力是视力结果的唯一预测因素（P = 0.043）。结论：治疗前 AF 并不是继发于年龄相关性黄斑变性的 CNV 的玻璃体内贝伐单抗单药治疗的治疗反应的预测因子。
Purpose: Foveal autofluorescence (AF) has been suggested to be a potential predictor of treatment outcome in choroidal neovascularization (CNV) secondary to age-related macular degeneration and could be a useful marker to help prognosticate for patients and for clinical trials. This retrospective study aims to determine if pretreatment foveal AF can predict treatment response to intravitreal bevacizumab monotherapy in CNV secondary to age-related macular degeneration.Methods: Ninety-five eyes (85 patients) with naive CNV secondary to age-related macular degeneration, treated with intravitreal bevacizumab monotherapy were included in this study. Lesion size, CNV type on fluorescein angiography, pretreatment best-corrected visual acuity, and foveal AF pattern (intact/nonintact) were used as predictors. Multivariate linear regression and logistic regression were performed using best-corrected visual acuity change and anatomical response at 6 months as the dependent variables separately.Results: Pretreatment foveal AF (intact or nonintact) did not predict visual outcome (P = 0.17) nor did lesion size (P = 0.2) or CNV type (P = 0.61). Foveal AF did correlate with the visual acuity but it did not predict any treatment response. Pretreatment best-corrected visual acuity was the only predictive factor for the visual outcome (P = 0.043).Conclusion: Pretreatment AF is not a predictor for the treatment response to intravitreal bevacizumab monotherapy in eyes with CNV secondary to age-related macular degeneration.